NHE3 Inhibitors
2 drugsAbout NHE3
The Sodium-Hydrogen Exchanger 3 (NHE3) is a membrane protein that transports sodium ions and protons across cell membranes, primarily in the gastrointestinal tract and kidneys, maintaining electrolyte balance and fluid volume.
NHE3 is a therapeutic target due to its role in electrolyte balance, though no genetic evidence currently links it to specific diseases. Two FDA-approved drugs, XPHOZAH and IBSRELA, modulate NHE3 activity, demonstrating its potential for treating various disorders.
NHE3 is targeted by two FDA-approved small molecule drugs: XPHOZAH and IBSRELA, both from ARDELYX INC. These drugs address therapeutic areas outside of common categories, highlighting the potential of NHE3 modulation.
Top NHE3 Drugs
ARDELYX INC is the only company with approved drugs targeting NHE3.
The market is highly concentrated, presenting a barrier to entry for new companies.
NHE3 Drug Modality Landscape
Modalities
Routes of Administration
NHE3 is amenable to small molecule drugs, with oral options available for convenient dosing.
The exclusive use of small molecules suggests an opportunity to explore other modalities like antibodies or peptides.
NHE3 Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on NHE3. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 3 | 2 | 0 | 1 | 100% |
| Phase 3 | 7 | 5 | 0 | 2 | 100% |
| Phase 4 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
NHE3 Drug Approval Timeline (2019 - 2023)
The first drug targeting NHE3 was approved in 2019 (IBSRELA), with the most recent approval in 2023 (XPHOZAH).
The recent approval of XPHOZAH indicates continued interest and potential in targeting NHE3.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 5 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on NHE3. A trial counts if an approved drug acting on NHE3 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.